SCHEMBL6900631

SCHEMBL6900631

O=C(Cn1cccc1C(=O)O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
MAPT P10636 2/20 0.60
RECQL P46063 2/20 0.60
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
ALOX12 P18054 1/20 0.60
KDM1A O60341 1/20 0.50
RCOR1 Q9UKL0 1/20 0.50
POLB P06746 1/20 0.47
GPR35 Q9HC97 1/20 0.47
TSHR P16473 1/20 0.46
GFER P55789 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP3A4 P08684 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
CES1 P23141 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2336600 0.87 GSK3B (0.51) MEN1KMT2AMAPTRECQLALDH1A1
SCHEMBL2332245 0.87 MAPT (0.57) MEN1KMT2AMAPTRECQLALDH1A1
SCHEMBL2331508 0.83 MAPT (0.43) MEN1KMT2AMAPTRECQLALDH1A1
SCHEMBL5516710 0.81 KMT2A (0.68) MEN1KMT2AMAPTRECQLALDH1A1
SCHEMBL17962565 0.78 ALDH1A1 (0.50) MEN1KMT2AMAPTRECQLALDH1A1
SCHEMBL2327030 0.78 LMNA (0.50) MEN1KMT2AMAPTRECQLALDH1A1
SCHEMBL10656937 0.76 TSHR (0.59) MEN1KMT2AMAPTRECQLALDH1A1
SCHEMBL27001661 0.76 POLB (0.45) MEN1KMT2AMAPTRECQLALDH1A1
SCHEMBL9023262 0.75 NPC1 (0.49) MEN1KMT2AMAPTRECQLALDH1A1
SCHEMBL9329215 0.75 RECQL (1.00) MEN1KMT2AMAPTRECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540387-B2 Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2017-01-10 US disclosed
US-9540387-B2 Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2017-01-10 US disclosed
US-20160046642-A1 Compounds for Treating Respiratory Syncytial Virus Infections BIOTA SCIENT MANAGEMENT (AU) 2016-02-18 US disclosed
US-20160046642-A1 Compounds for Treating Respiratory Syncytial Virus Infections BIOTA SCIENT MANAGEMENT (AU) 2016-02-18 US disclosed
US-9163029-B2 Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2015-10-20 US disclosed
US-9163029-B2 Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2015-10-20 US disclosed
US-20140051697-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2014-02-20 US disclosed
US-20140051697-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2014-02-20 US disclosed
US-20110207728-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2011-08-25 US disclosed
US-20110207728-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2011-08-25 US disclosed
WO-2011094823-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207728-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS FURIN, SQOR, SUCNR1 MEN1 2753/4885KMT2A 3375/4885MAPT 4436/4885
US-20160046642-A1 Compounds for Treating Respiratory Syncytial Virus Infections FURIN, SQOR, SUCNR1 MEN1 2753/4885KMT2A 3375/4885MAPT 4436/4885
US-20140051697-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS FURIN, SQOR, SUCNR1 MEN1 2753/4885KMT2A 3375/4885MAPT 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.